These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 16372228)

  • 21. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
    Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of anti-TSH receptor antibodies (TRAb) to predict the outcome of the course of Graves' disease following withdrawal of antithyroid drug.
    Shoda Y; Akiyama H; Yamaguchi T; Inukai T; Kobayashi I; Kondo Y; Kobayashi S
    Exp Clin Endocrinol; 1991 Mar; 97(1):113-6. PubMed ID: 1677893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
    Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S; Shin DY; Song MK; Lee EJ
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease].
    Zöphel K; Wunderlich G; Koch R; Franke WG
    Nuklearmedizin; 2000; 39(4):113-20. PubMed ID: 10919162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A; Aleksić Z; Stojanović M
    Hell J Nucl Med; 2009; 12(2):146-50. PubMed ID: 19675869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum.
    Morgenthaler NG; Minich WB; Willnich M; Bogusch T; Hollidt JM; Weglöhner W; Lenzner C; Bergmann A
    Mol Cell Endocrinol; 2003 Dec; 212(1-2):73-9. PubMed ID: 14654252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C; Morgenthaler NG
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.